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Shortly after the ﬁrst description of the acquired immune
deﬁciency syndrome (AIDS) in 1981, the human immunodeﬁ-
ciency virus (HIV) was isolated, identiﬁed and characterized.
Since that time, a remarkable amount of experimental
work has been undertaken and, during those early years, I
believe no-one could have foreseen the development of such
a large body of knowledge relating to a virus infection.
The advancement of knowledge relating to HIV has pro-
vided tools for a better understanding of other human virus
infections, and much of the experience gained in HIV
research and testing has been transferred to and extrapo-
lated to other human chronic virus infections, such as those
caused by the hepatitis B and C viruses [1].
Because of the efforts made then and especially more
recently, we now know that HIV infection can be controlled
and, for the ﬁrst time in more than 25 years of broad-based
research, it has been announced that the life expectancy of
HIV-infected patients is the same as for those who are sero-
negative [2,3]. Many HIV-infected patients are now in their
second decade of active antiretroviral therapy (ART), which
usually means a combination of three of the over 25 cur-
rently licensed antiretroviral drugs that allow the suppression
of plasma viremia to be sustained below the limits of detec-
tion of currently available assays [4,5].
When one considers that ART has transformed an invari-
ably fatal illness into one that can be managed with one or a
few pills daily, one realizes that, in general, the results relat-
ing to HIV infection represent one of the major success sto-
ries of modern biomedical research.
However, as is usual in science, the more remarkable the
new ﬁndings and the faster their achievement, the greater
the number of subjects that have to be addressed. Indeed,
many aspects of HIV infection remain to be elucidated and,
little by little, as the research goes ahead, new and more
intriguing issues that open new and fascinating questions
come to the attention of researchers [6,7].
What do the respective roles of the virus, immune activa-
tion and lack of cellular regeneration contribute to disease
pathogenesis? Why don’t natural African non-human primate
hosts develop the disease after infection, despite high viral
loads? What is the basis for the resistance to disease pro-
gression seen in some HIV-1 infected individuals? Is the erad-
ication of the infection feasible? And, from a more practical
point of view, how can we develop a protective immunity to
HIV?
As far as clinical virology issues are concerned, we now
know how to identify correctly infected people using very
sensitive and appropriate assays, and how to follow-up prop-
erly the course of infection mainly by measuring CD4 cells
and HIV-RNA loads in the blood. For quantitative HIV-RNA
detection there are various tests; examples are End-Point
PCR, NASBA, TMA, branched-DNA, and Real-Time-PCR [8].
All these tests have high sensitivity and high throughput per-
formance and allow HIV infections to be monitored from
the very early phases of infection. Both before starting and
during therapy the sensitivity of the virus to different drugs
and its bio/virological characteristics can be measured by
studying and identifying the phenotype of the virus, and by
nucleic acid sequencing looking at the speciﬁc mutations in
the viral genome associated with drug resistance or with a
speciﬁc phenotype. However, the remarkable ability of HIV
to mutate poses signiﬁcant problems not only for the devel-
opment of effective vaccine and eradication therapeutic strat-
egies but also for diagnostic and monitoring strategies.
Virologic assays continue to evolve to meet the needs of
HIV-infected patients and their management and it is known
that their use in clinical virology have today a fundamental
role in HIV- disease management. This theme section
addresses the above issues, and tries to give some recent
information on the clinical and diagnostic usefulness of the
current methods of addressing them.
We are not attempting to address the usefulness of
‘genomics’, with all its associated tools and techniques, in the
monitoring of HIV infection. Indeed, we ﬁrmly believe that
since substantially faster and cheaper sequencing methods
are continually being developed, full sequencing of all viral
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variants harbouring the host will provide new insights into a
comprehensive understanding of the natural history of HIV
infection; however, at present, we still lack the cultural ‘tool’
necessary to relate the ﬁndings from genomics to different
clinical situations. Indeed, the tools and techniques proposed
in the following reviews are already available and applicable
from a clinical viewpoint and, more importantly, their
usefulness is appreciated and used by most clinical virology
laboratories.
Indirectly, and taken together, the reviews emphasize that
the future for HIV infection, as broadly demonstrated in the
past, is linked to its ability to quickly and effectively mutate;
they reinforce the concept that, although much work has
been done, the proper application of current and developing
technology for monitoring HIV-infected patients under treat-
ment is a key issue in achieving the goal of antiretroviral
treatment, that is, to suppress HIV replication thereby maxi-
mally preventing variability in the virus.
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